Related Experiment Video
Updated: Jan 5, 2026

Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies
Published on: October 4, 2024
SCOT-HEART trial: reshuffling our approach to stable ischemic heart disease
Sagar B Amin1, Arthur E Stillman1
1Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA.
Insights
Coronary CT angiography (CCTA) significantly reduced heart events compared to standard care in stable ischemic heart disease patients. This diagnostic approach offers better outcomes without increasing invasive procedures.
Area of Science:
- Cardiology
- Diagnostic Imaging
- Preventive Medicine
Background:
- Stable ischemic heart disease diagnosis traditionally relies on functional testing.
- Coronary CT angiography (CCTA) is emerging as a superior diagnostic tool.
- The SCOT-HEART trial provides key evidence for CCTA's benefits.
Purpose of the Study:
- To review the SCOT-HEART trial findings.
- To discuss the impact of CCTA on stable ischemic heart disease management.
- To highlight the advantages of a CCTA-first strategy.
Main Methods:
- Analysis of the SCOT-HEART trial data.
- Comparison of CCTA with standard care in stable ischemic heart disease patients.
- Evaluation of outcomes over a 5-year follow-up period.
Main Results:
- CCTA implementation significantly reduced coronary heart disease death and myocardial infarction.
- No significant increase in invasive coronary angiography rates was observed.
- CCTA demonstrated high negative predictive value and identified nonobstructive disease.
Conclusions:
- CCTA is a pivotal diagnostic exam for stable ischemic heart disease.
- A CCTA-first strategy optimizes patient care and medical therapy.
- The SCOT-HEART trial supports the paradigm shift towards CCTA in diagnosing coronary artery disease.
Abstract:
The role of diagnostic testing in triaging patients with stable ischemic heart disease continues to evolve towards recognizing the benefits of coronary CT angiography (CCTA) over functional testing. The SCOT-HEART (Scottish Computed Tomography of the HEART) trial highlights this paradigm shift finding a significant reduction of death from coronary heart disease or non-fatal myocardial infarction without a significant increased rate of invasive coronary angiography over a 5 year follow-up period when implementing CCTA with standard care vs standard care alone. The better negative predictive value and ability to identify nonobstructive coronary artery disease to optimize medical therapy highlight the benefits of a CCTA first strategy. With the advent of noninvasive fractional flow reserve (FFR) and widespread availability and ease of CT, CCTA continues to establish itself as a pivotal diagnostic exam for patients with stable ischemic heart disease. In this commentary, we review the SCOT-HEART trial and its impact on CCTA for patients with stable ischemic heart disease.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease II: Pathophysiology

